Trends in neovascular glaucoma management: Practice patterns of glaucoma and retina specialists in the United States
Open Access
- 4 December 2019
- journal article
- Published by Scientific Scholar in American Journal of Ophthalmic Clinical Trials
Abstract
Purpose: To characterize practice patterns between and within retina and glaucoma subspecialists treating neo- vascular glaucoma (NVG). Methods: Preliminary survey study consisting of 8-questions developed based on actual clinical cases presenting to our institution between June 2014 and June 2016. The survey was administered in the form of clinical vignettes and circulated electronically using Survey Monkey ©. to members of the American Glaucoma Society (AGS) and American Society of Retina Specialists (ASRS). Results: 109 glaucoma and 130 retina specialists initiated the survey. For initial management of patients with good visual acuity (VA) and NVG, retina specialists preferred anti-VEGF therapy (P < 0.01) while glaucoma specialists preferred combined anti-VEGF and tube shunt surgery (P < 0.01). Following initial therapy in patients with good VA, glaucoma specialists preferred surgery (P < 0.01) and retina specialists preferred PRP (P < 0.01). In patients with poor VA, PRP and anti-VEGF were equally favored, with a preference for surgery by glaucoma specialists compared to retina specialists (P < 0.01). Conclusion: NVG is a complex problem within the field of ophthalmology that often requires management by both retina and glaucoma specialists. Agreement between both subspecialties for the use of anti-VEGF agents as first line treatment, either alone or in concert with other therapies was noted. Multiple differences exist in next step in therapy and long-term management. Future consensus panels may mitigate discrepancies in NVG management and work toward development of care paths for more efficient care delivery.Keywords
This publication has 22 references indexed in Scilit:
- Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic RetinopathyJAMA Ophthalmology, 2018
- Current management of glaucoma and vascular occlusive diseaseCurrent Opinion in Opthalmology, 2016
- Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumabEye, 2015
- Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic RetinopathyJAMA, 2015
- Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing ahmed glaucoma valve implantation: 2‐year follow‐upActa Ophthalmologica, 2014
- Efficacy of Intravitreal Bevacizumab With Panretinal Photocoagulation Followed by Ahmed Valve Implantation in Neovascular GlaucomaJournal of Glaucoma, 2013
- Anti-vascular endothelial growth factor for neovascular glaucomaEmergencias, 2013
- COMBINATION INTRAVITREAL BEVACIZUMAB/PANRETINAL PHOTOCOAGULATION VERSUS PANRETINAL PHOTOCOAGULATION ALONE IN THE TREATMENT OF NEOVASCULAR GLAUCOMARetina, 2008
- Argon laser panretinal photocoagulation in ischemic central retinal vein occlusionAlbrecht von Graefes Archiv für Ophthalmologie, 1990
- Neovascular GlaucomaOphthalmology, 1984